Moderate
Probable
描述
Bupropion, a CYP2D6 inhibitor, significantly increases aripiprazole plasma concentrations, increasing the risk of dose-dependent adverse effects.
机制
Bupropion inhibits CYP2D6 moderately to potently, reducing aripiprazole metabolism and raising its AUC; the active metabolite dehydro-aripiprazole ratio also shifts.
临床意义
Aripiprazole exposure may increase substantially; adverse effects (akathisia, metabolic effects) may become clinically prominent.
处理措施
Reduce aripiprazole dose when adding bupropion; monitor for adverse effects and adjust dose based on clinical response.